

**ASX MEDIA RELEASE**

26 May 2023

# Clarity to present at ASCO and SNMMI 2023 Annual Meetings

## Highlights

- Four abstracts have been accepted by the American Society of Clinical Oncology (ASCO) and Society of Nuclear Medicine and Molecular Imaging (SNMMI) 2023 Annual Meetings, showcasing the data from Clarity’s oncology portfolio.
- Abstracts of Clarity’s diagnostic clinical study, PROPELLER, comparing <sup>64</sup>Cu SAR-bisPSMA to the current standard-of-care in the diagnostic detection of prostate cancer lesions, <sup>68</sup>Ga PSMA-11, were accepted by both ASCO and SNMMI 2023 Annual Meetings.
- Two pre-clinical abstracts, accepted by the SNMMI 2023 Annual Meeting, showcase results on new targets and oncology indications using Clarity’s Targeted Copper Theranostics (TCTs), highlighting the potential to expand the platform to multiple malignancies.

**Clarity Pharmaceuticals** (ASX: CU6) (“Clarity”, “the Company”), a clinical stage radiopharmaceutical company with a mission to develop next-generation products that improve treatment outcomes for children and adults with cancer, is pleased to announce that new data will be presented at the upcoming ASCO and SNMMI 2023 Annual Meetings, covering clinical and pre-clinical results in multiple oncology indications. The data showcases the breadth of Clarity’s TCT platform of developing multiple products to treat a multitude of cancers with high unmet medical needs.

**Clarity’s Executive Chairman, Dr Alan Taylor, commented,** “The ASCO and SNMMI Annual Meetings are the most prestigious conferences in oncology and nuclear medicine, respectively. We are delighted that our data has been accepted for presentation at these major forums. The abstracts accepted for presentation highlight the exciting possibilities of our next-generation TCT radiopharmaceuticals, addressing some of the challenges of the current-generation of radiopharmaceutical products and expanding the platform into multiple malignancies. We look forward to further developing our existing as well as novel TCT products as we get closer to our ultimate goal of improving treatment outcomes for children and adults with cancer.”

## Data to be presented at 2023 ASCO and SNMMI Annual Meetings

Product	Abstract Title	Authors	Conference
<sup>64</sup> Cu SAR-bisPSMA	<sup>64</sup> Cu-SAR-bisPSMA (PROPELLER) Positron Emission Tomography (PET) Imaging in Patients With Confirmed Prostate Cancer	Eva Lengyelova, Veronica Wong, Nat Lenzo, Michelle Parker, Louise Emmett	2023 ASCO Annual Meeting <i>Session title: Genitourinary Cancer – Prostate, Testicular, and Penile</i> <i>Session date: 3<sup>rd</sup> June</i> <i>Session time: 8am-11am</i> <i>Poster Board: 133</i> <i>Abstract number: 5039</i>
<sup>64</sup> Cu SAR-bisPSMA	Comparison of PET/CT in Subjects with Confirmed Prostate Cancer Using <sup>64</sup> Cu SAR-bisPSMA and <sup>68</sup> Ga PSMA-11	Eva Lengyelova, Veronica Wong, Nat Lenzo, Michelle Parker, Louise Emmett	2023 SNMMI Annual Meeting

<sup>64</sup> Cu/ <sup>67</sup> Cu SAR-bisRGD	Cu-64/Cu-67 SAR-bisRGD as a theranostic for cancer	Ellen van Dam, Lachlan McInnes, Benjamin Blyth, Jessica Van Zuylekom, Buck E. Rogers, Cristian Wieczorek Villas Boas, Yi Rao, Jason S. Lewis, Kurt Gehlsen, Jeff Norenberg, Matt Harris	2023 SNMMI Annual Meeting
<sup>64</sup> Cu SAR-5B1 and <sup>64</sup> Cu SAR-bisRGB	Copper-67 based targeted radiotherapy primes immunologically cold pancreatic adenocarcinoma for immunotherapy	Yi Rao, Tara Viray, Ellen Van Dam, Kurt Gehlsen, Matt Harris, Lachlan McInnes, Jeff Norenberg, Jason S Lewis	2023 SNMMI Annual Meeting

Poster abstracts will be available on Clarity’s official website after their presentation at the 2023 ASCO and SNMMI Annual Meetings: [claritypharmaceuticals.com/pipeline/scientific\\_presentations](https://www.claritypharmaceuticals.com/pipeline/scientific_presentations)

**About Clarity Pharmaceuticals**

Clarity is a clinical stage radiopharmaceutical company focused on the treatment of serious disease. The Company is a leader in innovative radiopharmaceuticals, developing targeted copper theranostics based on its SAR Technology Platform for the treatment of cancer in children and adults.

[www.claritypharmaceuticals.com](http://www.claritypharmaceuticals.com)

**For more information, please contact:**

**Clarity Pharmaceuticals**

Dr Alan Taylor  
**Executive Chairman**  
[ataylor@claritypharm.com](mailto:ataylor@claritypharm.com)

Catherine Strong  
**Investor/Media Relations**  
[cstrong@citadelmagnus.com](mailto:cstrong@citadelmagnus.com)  
+61 406 759 268

*This announcement has been authorised for release by the Executive Chairman.*